A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases

Trial Profile

A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2018

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Brain metastases; Malignant melanoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 27 Jun 2018 Status changed from recruiting to active, no longer recruiting.
    • 05 Jun 2018 Interim results (n=39) assessing efficacy of Pembrolizumab in patients with non-small cell lung cancer, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top